TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06610877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Neuromodulation
Description: Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction). Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound neuromodulation
Description: Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction) in each patient. Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
Study: NCT06403709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
Description: These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
Study: NCT06610487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT1
Description: Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT1
Description: Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06609980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous fecal matter transplant
Description: Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
Study: NCT06609421

Intervention type: OTHER
Intervention: Informative Appointment
Description: The only intervention involving the participants is non-clinical, which is an extra 30-minute informative telephone appointment added to the standard care consultation schedule of interested IVF patients where they will be presented with a digital consent PDF form to sign by a study nurse or clinically trained research personnel. Participants will be in the study for 24-30 months. During this time their discarded, unfertilised oocytes and follicular fluid collected during routine oocyte retrieval along with information from their electronic medical records will be collected and analysed.

Intervention type: OTHER
Intervention: Informative Appointment
Description: The only intervention involving the participants is non-clinical, which is an extra 30-minute informative telephone appointment added to the standard care consultation schedule of interested IVF patients where they will be presented with a digital consent PDF form to sign by a study nurse or clinically trained research personnel. Participants will be in the study for 24-30 months. During this time their discarded, unfertilised oocytes and follicular fluid collected during routine oocyte retrieval along with information from their electronic medical records will be collected and analysed.
Study: NCT06331702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-drived inactive Japanese encephalitis vaccine
Description: 0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered in the deltoid area of lateral arm by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vero cell-drived inactive Japanese encephalitis vaccine
Description: 0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered in the deltoid area of lateral arm by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella Vaccine
Description: 0.5ml for each dose (after dissolving), manufactured by Shanghai Institute of Biological Products CO., LTD, administered in the lower part of the deltoid area of lateral arm, by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Mumps-Rubella Vaccine
Description: 0.5ml for each dose (after dissolving), manufactured by Shanghai Institute of Biological Products CO., LTD, administered in the lower part of the deltoid area of lateral arm, by subcutaneous injection.
Study: NCT06728163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written education group
Description: group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR educational material + breathing relaxation with verbal instruction
Description: group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. Verbal instructions for breathing are provided for about 3 minutes and 3 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR educational material + breathing relaxation with music intervention
Description: group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written educational material + breathing relaxation with music intervention.
Description: group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.~The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.
Study: NCT06729060

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Motor Imagery and Physical Performance
Description: For 15 minutes you will physically eliminate targets by clicking on them in the Aim Lab Trainer (Physical Performance Part).~Then, on a screen divided into 60 squares, the target will appear and disappear in a random square for 5 seconds. At the same time, the metronome will give a warning sound at each new target. The stimulus will come every five seconds and each time the stimulus comes, the target will imagine that it has disappeared. In the next 5 seconds, the stimulus will come again in a different place and he will imagine that he has destroyed it again. In the first two weeks, this will happen for 60 stimuli with 5 second intervals.~(60target\*5sec=300sec \*3=900sec/60 =15 min). In the next 2 weeks, the interval will be reduced by 1 second and in the last two weeks it will not be reduced. But the duration will always be 15 minutes (Motor Imagery Part).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance
Description: For 30 minutes, they will eliminate the Aim Lab Trainer test by clicking quickly and accurately with their dominant hands. The physical performance practice to be applied both in this group and in the Motor Imagery and Physical Performance Combination Group is the same and will be applied in the same way for 8 weeks
Study: NCT06729125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial photobiomodulation
Description: Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises training
Description: balance exercises and others
Study: NCT06728722

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound detection of body composition
Description: Muscle mass and fat thickness The examiner will use a five-site protocol. The protocol includes the examination of quadriceps on four sides and one bicep will be used The technique is reported by USVALID (Arabella, 2020) GRADING OF QUALITY OF ULTRASOUND SCANS - Muscle quality (fat and fibrotic infiltration) grading for each scan~1. = Muscle fascia and bone surface visible~2. = muscle fascia and bone surface still possible to spot~3. = muscle fascia and bone surface not distinguishable; no evaluation possible~The FLUID protocol for edema will be done as follows: MEASURING POINTS 36 points, GRADING OF QUALITY: The examiner will use a 5-point scale of ultrasonic subcutaneous edema grade (USEG) to evaluate subcutaneous edema at each site based on echo intensity, tissue transparency, and fluid properties.~Day zero, day 2 then Every 2 days if extended length.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound detection of body composition
Description: Muscle mass and fat thickness The examiner will use a five-site protocol. The protocol includes the examination of quadriceps on four sides and one bicep will be used The technique is reported by USVALID (Arabella, 2020) GRADING OF QUALITY OF ULTRASOUND SCANS - Muscle quality (fat and fibrotic infiltration) grading for each scan~1. = Muscle fascia and bone surface visible~2. = muscle fascia and bone surface still possible to spot~3. = muscle fascia and bone surface not distinguishable; no evaluation possible~The FLUID protocol for edema will be done as follows: MEASURING POINTS 36 points, GRADING OF QUALITY: The examiner will use a 5-point scale of ultrasonic subcutaneous edema grade (USEG) to evaluate subcutaneous edema at each site based on echo intensity, tissue transparency, and fluid properties.~Day zero, day 2 then Every 2 days if extended length.
Study: NCT06728852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Vorolanib
Description: This study utilizes Vorolanib, a novel angiogenesis inhibitor, as a monotherapy for advanced non-small cell lung cancer (NSCLC) patients who have failed at least two lines of systemic therapy. Vorolanib is administered orally at a dosage of 300 mg daily. The intervention focuses on its efficacy and safety as a third-line or beyond treatment, aiming to improve progression-free survival (PFS) and other clinical outcomes. Vorolanib targets VEGFR, PDGFR, and other tyrosine kinases, distinguishing it from other therapies by its enhanced anti-angiogenesis properties and tolerable safety profile in late-stage cancer treatment.
Study: NCT06729788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICON resin infiltration Material group in vivo
Description: The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resin-based fissure sealant group in vivo
Description: The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICON resin infiltration in vitro
Description: The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK) in vitro

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resin-based fissure sealant in vitro
Description: The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael) in vitro
Study: NCT05366426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG biofeedback program:
Description: Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EMG biofeededback:
Description: 3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).

Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic floor muscle training home exercise program:
Description: Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training home exercise program:
Description: Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pelvic floor muscle training home exercise program:
Description: Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
Study: NCT05717439

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5-R
Description: A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5-R
Description: A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5-R
Description: A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5-R
Description: A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5-R
Description: A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.

Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.

Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
Study: NCT06115655

Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA methylation detection
Description: Extract cfDNA from bile and plasma, and perform methylation detection.

Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA methylation detection
Description: Extract cfDNA from bile and plasma, and perform methylation detection.
Study: NCT04698434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: each group was given a single intravenous dose of the corresponding esketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: each group was given a single intravenous dose of the corresponding esketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: each group was given a single intravenous dose of the corresponding esketamine.
Study: NCT06551753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality app
Description: virtual reality app
Study: NCT04763512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact Cow's Milk Protein Formula
Description: Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially Hydrolysed Whey Formula
Description: Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
Study: NCT05338463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon Cream
Description: 1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks
Study: NCT05955482

Intervention type: OTHER
Intervention: NuvoAir Clinical Service
Description: The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
Study: NCT05632614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity IMST
Description: Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-intensity IMST
Description: Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
Study: NCT05033132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab + Zalifrelimab
Description: An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
Study: NCT05717439

Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.

Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.

Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.

Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
Study: NCT05903547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Prineo
Description: For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Suture
Description: For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
Study: NCT05462158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Nudges on CKD Testing
Description: The investigators will examine the impact of different messages on different dimensions of testing for CKD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Nudges on CKD Testing
Description: The investigators will examine the impact of different messages on different dimensions of testing for CKD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Nudges on CKD Testing
Description: The investigators will examine the impact of different messages on different dimensions of testing for CKD
Study: NCT04532229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab+CRT(concurrent IMRT and TMZ)
Description: Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ